Drug resistance in B-cell chronic lymphocytic leukemia: Predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay

Cytometry Part B - Clinical Cytometry

Volumn 72, Issue 3, 2007, Pages 189-195

  Zhong, Yanping ^a   Bakke, Antony C ^a   Fan, Guang ^a   Braziel, Rita M ^a   Gatter, Ken M ^a   Leis, Jose F ^b   Maziarz, Richard T ^b   Huang, James Z ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chronic lymphocytic leukemia; Cytotoxicity assay; Drug sensitivity; Flow cytometry

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; FLUDARABINE; PENTOSTATIN; PREDNISOLONE; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CELL ASSAY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENES, P53; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; TOXICITY TESTS; TREATMENT OUTCOME; VIDARABINE;

EID: 34247581207     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20117     Document Type: Article

References (24)

1. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2004:163-183.
2. Fenaux P, Preudhomme C, Lai JL, Quiquandon I, Jonveaux, P, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre MH, Earners F, Berger R, Kerckaert P. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: A report on 39 cases with cytogenetic analysis. Leukemia 1992;6:246-250.
3. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
4. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ. Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-1184.
5. Stilgenbauer S, Dohner H. Molecular genetics and its clinical relevance. Hematol Oncol Clin North Am 2004;18:827-848 (review, viii).
6. el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW. p53 Gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452-3459.
7. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 Mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-3157.
8. Morabito F, Stelitano C, Callea I, Dattola A, Console G, Pucci G, Iacopino P, Callea V, di Raimondo F, Brugiatelli M. In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia. Br J Haematol 1998;102:528-531.
9. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-1062.
10. Johnston JB, Daeninck P, Verburg L, Lee K, Williams G, Israels LG, Mowat MR, Begleiter A. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997;26:435-449.
11. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA. In vitro chemosensitivity of chronic lymphocytic leukemia to purine analogues-correlation with clinical course. Leukemia 1998;12:1230-1235.
12. Pettitt AR, Sherrington PD, Cawley JC. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukemia. Br J Haematol 1999;106:1049-1051.
13. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 2003;10:477-484.
14. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 2004;104:1428-1434.
15. Stankovic T, Hubank M, Cronin D, Stewart GS, Fletcher D, Bignell CR, Alvi AJ, Austen B, Weston VJ, Fegan C, Byrd PJ, Moss PA, Taylor AM. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood 2004;103:291-300.
16. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 Dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98:814-822.
17. Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet 1991;337:711-714.
18. Larsson R, Kristensen J, Sandberg C, Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992;50:177-185.
19. Callea V, Stelitano C, Callea I, Console G, Brugiatelli M, Morabito F. In vitro drug-induced cytotoxicity predicts clinical response to high-dose chlorambucil in B-cell chronic lymphocytic leukemia. Haematologica 1999;84:863-864.
20. Bosanquet AG, Johnson SA, Richards SM. Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay. Br J Haematol 1999;106:71-77.
21. Bosanquet AG, Bell PB. Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood 1996;87:1962-1971.
22. Bosanquet AG, Bell PB. Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leuk Res 1996;20:143-153.
23. Bosanquet AG, Burlton AR, Bell PB, Harris AL. Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: Results with 8-chloro-cAMP. Br J Cancer 1997;76:511-518.
24. Twentyman PR, Fox NE, Rees JK. Chemosensitivity testing of fresh leukaemia cells using the MTT colorimetric assay. Br J Haematol 1989; 71:19-24.